TransMedics Q3 revenue $143.8M (+32% YoY); raises FY2025 guidance to $595-605M

TransMedics Group, Inc.

2025-Q3 EPS reported $2.28 revenue$444,730,000

Revenue $143.8M, up 32% vs Q3 2024; net income $24.3M ($0.66 diluted EPS) vs $4.2M a year ago.
Gross margin improved to 59% from 56%; cash balance $466.2M as of Sept 30.
FY2025 revenue guidance raised to $595-605M (midpoint $600M, 36% growth); prior range was $585-605M.
Announced strategic collaboration with Mercedes-Benz to deploy V-Class vehicles for organ transport in Italy.
Owned 21 aircraft as of Sept 30 (22 as of Oct 29); OCS growth driven by NOP and aviation fleet expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.